Search Result

Results for "

Fusion Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (2) Apoptosis (8) Arenavirus (1) Atg8/LC3 (1) Autophagy (8) Bacterial (3) EGFR (1) Epigenetic Reader Domain (1) FGFR (1) Histone Methyltransferase (3) HIV (9) HSV (1) Influenza Virus (7) Interleukin Related (1) Isotope-Labeled Compounds (1) Mitophagy (1) mTOR (2) p62 (1) PD-1/PD-L1 (1) PKA (1) Proton Pump (1) RET (1) ROS Kinase (1) RSV (7) SARS-CoV (5) TAM Receptor (1) TGF-beta/Smad (1) TNF Receptor (1) Trk Receptor (6) VEGFR (1) WDR5 (1)
By Research Areas:	Cancer (26) Cardiovascular Disease (2) Infection (27) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122907

JNJ4796	Influenza Virus	Infection
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .

HY-19810

MI-538

3 Publications Verification

Epigenetic Reader Domain Cancer

MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC₅₀ of 21 nM.
HY-P0052A

Enfuvirtide acetate

2 Publications Verification

T20 acetate; DP178 acetate
HIV Infection

Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.

MI-538 3 Publications Verification	Epigenetic Reader Domain	Cancer
MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC₅₀ of 21 nM.

Enfuvirtide acetate 2 Publications Verification T20 acetate; DP178 acetate	HIV	Infection
Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.

HY-146108

RSV-IN-5	RSV	Infection
RSV-IN-5 (Compound 4) is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus (RSV) fusion proteins. RSV-IN-5 exhibits potent anti-RSV activities against not only wild-type A2 F protein (EC₅₀=2.0 nM), but also D486N-mutant F protein (EC₅₀=8.1 nM) .

HY-19874

RFI-641
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), with an IC₅₀ of 50 nM. RFI-641 inhibit binding and fusion of enveloped virus via interaction with the viral fusion protein .

HY-11097

TMC353121

5 Publications Verification

RSV Infection

TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC₅₀ of 9.9.
HY-16727

Presatovir

4 Publications Verification

GS-5806
RSV Infection

Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC₅₀ value of 0.43 nM .
HY-P0052

Enfuvirtide

2 Publications Verification

T20; DP178
HIV Infection

Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide.

TMC353121 5 Publications Verification	RSV	Infection
TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC₅₀ of 9.9.

Presatovir 4 Publications Verification GS-5806	RSV	Infection
Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC₅₀ value of 0.43 nM .

Enfuvirtide 2 Publications Verification T20; DP178	HIV	Infection
Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide.

HY-76648

NBD-556	HIV	Infection
NBD-556, a CD4 mimetic, is a potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels .

HY-112180

Rilematovir 3 Publications Verification JNJ-678; JNJ-53718678	RSV	Infection
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.

HY-12994

VP-14637

MDT-637

MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC₅₀ of 1.42 ng/mL.

VP-14637 MDT-637
MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC₅₀ of 1.42 ng/mL.

HY-129111

EACC 3 Publications Verification	Autophagy	Infection Neurological Disease
EACC is a reversible autophagy inhibitor, which can block autophagic flux. EACC selectively inhibits the translocation of autophagosome-specific SNARE Stx17 thereby blocking autophagosome-lysosome fusion .

HY-B0795

MHY1485 105+ Cited Publications	mTOR Autophagy	Cancer
MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes .

HY-114437

Fusion Inhibitory Peptide Z-D-Phe-Phe-Gly-OH; FIP; Virus Replication Inhibitory Peptide	Influenza Virus	Infection
Fusion Inhibitory Peptide (Z-D-Phe-Phe-Gly-OH, FIP, Virus Replication Inhibitory Peptide) is a potent inhibitor of the virus replication, by inhibiting the membrane fusing activity of a viral glycoprotein .

HY-P5497

C34 peptide	HIV	Others
C34 peptide is a biological active peptide. (This C34 peptide, also known as HR2, belongs to the helical region of gp41 of HIV, C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion, C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.)

HY-W048674

Fmoc-Ser(Ac)-OH Fmoc-O-acetyl-L-serine	Amino Acid Derivatives	Infection
Fmoc-Ser(Ac)-OH (Fmoc-O-acetyl-L-serine) is a Serine derivative. Fmoc-Ser(Ac)-OH can be used for the preparation of broad-spectrum coronavirus membrane fusion inhibitor .

HY-124871

LASV inhibitor 3.3	Arenavirus	Infection
LASV inhibitor 3.3 is a Lassa fever virus (LASV) inhibitor. LASV inhibitor 3.3 binds with LASV glycoprotein (GP) and promotes virus membrane fusion and infection. LASV inhibitor 3.3 can be used for LASV infection research .

HY-146807

Type II TRK inhibitor 1	Trk Receptor	Cancer
Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKA ^G667C and ETV6-TRKC ^G696C fusion proteins with IC₅₀s of 6 nM and 1.7 nM, respectively . Type II TRK inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-131059

CBS1117	Influenza Virus	Infection
CBS1117 is a virus entry inhibitor with an IC₅₀ of 70 nM for influenza A virus, A/Puerto Rico/8/34 (H1N1). CBS1117 interferes with the hemagglutinin (HA)-mediated fusion process .

HY-142645

RSV-IN-2	RSV	Infection
RSV-IN-2 is a potent dual inhibitor of wild-type and mutant respiratory syncytial virus fusion proteins (wild-type, EC₅₀ = 0.27 nM; D486N-mutant, EC₅₀ = 0.70 nM).

HY-119375

Syncytial Virus Inhibitor-1	Bacterial	Infection
Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC₅₀s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively .

HY-123475A

Sisunatovir hydrochloride 1 Publications Verification RV521 hydrochloride	RSV	Infection
Sisunatovir (RV521) hydrochloride, an orally available inhibitor of the *RSV fusion* (RSV-F) protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC₅₀**s of 1.4 nM and 1.0 nM, respectively .

HY-P1753

VIR-165	HIV	Infection
VIR-165 is a modified form of virus inhibitory peptide (VIRIP) that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains .

HY-P35433

Tifuvirtide T-1249	HIV	Inflammation/Immunology
Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .

HY-153386

CPD-1224	Anaplastic lymphoma kinase (ALK)	Cancer
CPD-1224 is an orally active derivative of ALK inhibitors to cereblon ligands. CPD-1224 targets to EML4-ALK oncogenic fusions, and degrades ALK and mutant L1196M/G1202R .

HY-108847

Etanercept 4 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-155514

HA-IN-1	Influenza Virus	Inflammation/Immunology
HA-IN-1 (compound 5g) is a Hemagglutinin (HA) ligand with high affinity, targeting to the trypsin cleavage site of HA. HA-IN-1 inhibits HA-mediated membrane fusion and reduces the pulmonary virus titer in vivo. HA-IN-1 is a potential influenza A virus (IAV) inhibitor, and an anti-influenza agent .

HY-108822

Rilonacept Arcalyst; IL 1 Trap; Interleukin 1 Trap	Interleukin Related	Inflammation/Immunology
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .

HY-14904A

Umifenovir hydrochloride 5+ Cited Publications	Influenza Virus SARS-CoV	Infection
Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-112698

CA-5f	p62 Atg8/LC3 Autophagy Apoptosis	Cancer
CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity .

HY-109142

Ziresovir 2 Publications Verification AK0529; RO-0529	RSV	Infection
Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC₅₀=3 nM) and highlights pharmacokinetics in animal species .

HY-131042

NNMTi 1 Publications Verification	Others	Metabolic Disease
NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC₅₀=1.2 μM) and selectively binds to the NNMT substrate-binding site residues . NNMTi promotes myoblast differentiation in vitro and enhances fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice .

HY-19587

Ditercalinium chloride NSC335153
Ditercalinium chloride is an anticancer agent. Ditercalinium chloride inhibits human DNA polymerase gamma activity. Ditercalinium chloride can deplete mitochondrial DNA in both mouse and human cells. Ditercalinium chloride is a potential ligand against the COMMD10-AP3S1 fusion protein .

HY-144321

Trk-IN-9	Trk Receptor	Cancer
Trk-IN-9 (Compound 12) is a potent inhibitor of TRK. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the apoptosis of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways. Trk-IN-9 has the potential for the research of NTRK-fusion cancers .

HY-148202

Influenza antiviral conjugate-1	HIV	Infection
Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13491

GNF-5837 3 Publications Verification	Trk Receptor	Cancer
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC₅₀ values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .

HY-141429

AS-99 free base	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-141429C

AS-99	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-P99720

Luspatercept ACE-536; luspatercept–aamt	TGF-beta/Smad	Metabolic Disease
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .

HY-112301

Pralsetinib 10+ Cited Publications BLU-667	RET	Cancer
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC₅₀s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .

HY-14904

Umifenovir 5+ Cited Publications	SARS-CoV Influenza Virus	Infection
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .

HY-100558

Bafilomycin A1 Maximum Cited Publications 369 Publications Verification BafA1	Proton Pump Autophagy Antibiotic Bacterial Apoptosis	Infection Cancer
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H ⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .

HY-153331

DDO-2213	WDR5	Cancer
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC₅₀ of 29 nM and a K_d value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research .

HY-141429A

AS-99 TFA	Histone Methyltransferase Apoptosis	Cancer
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-150072

DS89002333	PKA	Cancer
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC₅₀ of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-152292

Zidesamtinib NVL-520	ROS Kinase	Cancer
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC₅₀s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer .

HY-149368

SARS-CoV-2-IN-51	SARS-CoV	Infection
SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC₅₀s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .

HY-14904AS

Umifenovir-d6 hydrochloride	Isotope-Labeled Compounds Influenza Virus SARS-CoV	Infection
Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells[1][2]. Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity[3].

HY-150636

Autophagy-IN-1	Autophagy Apoptosis	Cancer
Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .

Cat. No.	Product Name	Target	Research Area

HY-P0052A

Enfuvirtide acetate

2 Publications Verification

T20 acetate; DP178 acetate
HIV Infection

Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.
HY-P0052

Enfuvirtide

2 Publications Verification

T20; DP178
HIV Infection

Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide.

HY-P4110

TAT-NSF222 Fusion Peptide	Peptides	Metabolic Disease Inflammation/Immunology
TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor .

HY-P4113

TAT-NSF700 Fusion Peptide	Peptides	Neurological Disease
TAT-NSF700 Fusion Peptide is a potent N-ethyl-maleimide-sensitive factor (NSF) inhibitor. TAT-NSF700 Fusion Peptide can readily permeate the cell membrane and interact with the intracellular organelle directly .

HY-114437

Fusion Inhibitory Peptide Z-D-Phe-Phe-Gly-OH; FIP; Virus Replication Inhibitory Peptide	Influenza Virus	Infection
Fusion Inhibitory Peptide (Z-D-Phe-Phe-Gly-OH, FIP, Virus Replication Inhibitory Peptide) is a potent inhibitor of the virus replication, by inhibiting the membrane fusing activity of a viral glycoprotein .

HY-P5497

C34 peptide	HIV	Others
C34 peptide is a biological active peptide. (This C34 peptide, also known as HR2, belongs to the helical region of gp41 of HIV, C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion, C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.)

HY-W048674

Fmoc-Ser(Ac)-OH Fmoc-O-acetyl-L-serine	Amino Acid Derivatives	Infection
Fmoc-Ser(Ac)-OH (Fmoc-O-acetyl-L-serine) is a Serine derivative. Fmoc-Ser(Ac)-OH can be used for the preparation of broad-spectrum coronavirus membrane fusion inhibitor .

HY-P1753

VIR-165	HIV	Infection
VIR-165 is a modified form of virus inhibitory peptide (VIRIP) that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains .

HY-P35433

Tifuvirtide T-1249	HIV	Inflammation/Immunology
Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .

HY-P5395

TAT-GluR23A Fusion Peptide	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P2200

Siamycin I BMY-29304	HIV Antibiotic	Infection Inflammation/Immunology
Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED₅₀s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .

Cat. No.	Product Name	Target	Research Area

HY-P99777

Ontorpacept TTI-621	Inhibitory Antibodies	Cancer
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-P99568

Telitacicept RC18	Inhibitory Antibodies	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .

HY-108847

Etanercept 4 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-108822

Rilonacept Arcalyst; IL 1 Trap; Interleukin 1 Trap	Interleukin Related	Inflammation/Immunology
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	Inhibitory Antibodies	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99720

Luspatercept ACE-536; luspatercept–aamt	TGF-beta/Smad	Metabolic Disease
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .

HY-P99268

Seribantumab SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .

Cat. No.	Product Name		Classification

HY-148202

Influenza antiviral conjugate-1		Alkynes
Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Fusion Inhibitors

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products